Literature DB >> 9788003

Disulfiram effects on acute cocaine administration.

E F McCance-Katz1, T R Kosten, P Jatlow.   

Abstract

Disulfiram (Antabuse) is being used in outpatient clinical trials to determine its efficacy as a treatment for cocaine dependence. This inpatient randomized, double-blind, placebo-controlled, within-subjects study was conducted to determine whether disulfiram (placebo, 250 or 500 mg/day) alters responses to acute intranasal cocaine (placebo, 1 or 2 mg/kg) administration. Effects of disulfiram on cocaine pharmacokinetics, physiological, and behavioral responses were determined. Disulfiram treatment increased plasma cocaine concentrations three to six times and significantly increased cocaine-associated cardiovascular responses, but did not significantly alter behavioral responses to cocaine. These interactions should be considered in the decision regarding disulfiram treatment in cocaine dependent patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788003     DOI: 10.1016/s0376-8716(98)00050-7

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  39 in total

Review 1.  Current concepts in pharmacotherapy of substance abuse.

Authors:  P C Gottschalk; L K Jacobsen; T R Kosten
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

Review 2.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

Review 3.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

4.  Disulfiram effects on responses to intravenous cocaine administration.

Authors:  Jennifer R Baker; Peter Jatlow; Elinore F McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2006-09-18       Impact factor: 4.492

Review 5.  [New developments in the pharmacotherapy of cocaine dependence].

Authors:  G Wiesbeck; K Dürsteler-MacFarland
Journal:  Nervenarzt       Date:  2006-09       Impact factor: 1.214

6.  Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry.

Authors:  Jill Hochreiter; Elinore F McCance-Katz; Jill Lapham; Qing Ma; Gene D Morse
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-04-01       Impact factor: 3.205

7.  Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV.

Authors:  Rajesh Ramakrishnan; Hongbing Liu; Andrew P Rice
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 8.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

9.  DBH gene as predictor of response in a cocaine vaccine clinical trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Sara C Hamon; David A Nielsen
Journal:  Neurosci Lett       Date:  2013-02-28       Impact factor: 3.046

10.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.